Indication
Gaucher's disease
Gaucher's disease is a rare, autosomal recessive lysosomal storage disorder caused by mutations in the *GBA1* gene, resulting in deficient activity of the lysosomal enzyme glucocerebrosidase. Read more about Gaucher's disease
12 drugs 10 manufacturers
Drugs that treat it
Common Gaucher's disease therapies.
YARGESA (miglustat)
MIGLUSTAT
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonGaucher's disease is a rare, autosomal recessive lysosomal storage disorder caused by mutations in the *GBA1* gene, resulting in deficient activity of the lysosomal enzyme glucocerebrosidase.
This deficiency leads to the progressive accumulation of glucocerebroside within the mononuclear phagocyte system, generating lipid-laden macrophages (Gaucher cells) primarily in the spleen, liver, and bone marrow.
Clinically, it manifests along a phenotypic spectrum characterized by hepatosplenomegaly, anemia, thrombocytopenia, and skeletal pathology, including bone pain, osteopenia, and avascular necrosis.
The condition can present without primary central nervous system involvement (type 1) or with severe, acute or chronic neuropathic complications (types 2 and 3).
- nih.gov
Gaucher's disease is a rare, autosomal recessive lysosomal storage disorder caused by mutations in the *GBA1* gene, resulting in deficient activity of the lysosomal enzyme glucocerebrosidase
- nih.gov
Gaucher's disease is a rare, autosomal recessive lysosomal storage disorder caused by mutations in the *GBA1* gene, resulting in deficient activity of the lysosomal enzyme glucocerebrosidase This deficiency leads to the progressive accumulation of glucocerebroside within the mononuclear phagocyte system, generating lipid-laden macrophages (Gaucher cells) primarily in the spleen, liver, and bone marrow Clinically, it manifests along a phenotypic spectrum characterized by hepatosplenomegaly, anemi...
- nih.gov
This deficiency leads to the progressive accumulation of glucocerebroside within the mononuclear phagocyte system, generating lipid-laden macrophages (Gaucher cells) primarily in the spleen, liver, and bone marrow The condition can present without primary central nervous system involvement (type 1) or with severe, acute or chronic neuropathic complications (types 2 and 3)
- nih.gov
This deficiency leads to the progressive accumulation of glucocerebroside within the mononuclear phagocyte system, generating lipid-laden macrophages (Gaucher cells) primarily in the spleen, liver, and bone marrow
- nih.gov
Clinically, it manifests along a phenotypic spectrum characterized by hepatosplenomegaly, anemia, thrombocytopenia, and skeletal pathology, including bone pain, osteopenia, and avascular necrosis The condition can present without primary central nervous system involvement (type 1) or with severe, acute or chronic neuropathic complications (types 2 and 3)
Personalize your experience
Follow Gaucher's disease and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.